ONO-4059 Study in Patients With Steroid-resistant Pemphigus
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age20+
SponsorOno Pharmaceutical Co., Ltd.
About this trial
ONO-4059-10:Multicenter, placebo-controlled, randomized, double-blind, Phase 3 study in patients with steroid-resistant pemphigus
Eligibility criteria
Qualifiers
Patients with a diagnosis of pemphigus
Patients with a re-increase in the pemphigus disease area index (PDAI) score before oral corticosteroid tapering to 10mg/day of prednisolone (PSL) equivalent
Disqualifiers
Patients with an active infection
Patients with malignancy
Patients with past history of serious allergy or anaphylaxis
Trial design
Treatments tested in this trial
- ONO-4059
- ONO-4059 placebo
Treatment groups
34 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov